EWTX EBITDA | Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. (EWTX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$61.94M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$54.12M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$46.86M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$42.61M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$61.94M	(m)	(m)	(m)	$32.00K*	-$42.47M*	(m)	$47.55M	(m)	(m)
2026-03-31	Reported	(m)	-$54.12M	(m)	(m)	(m)	$260.00K	-$42.54M	(m)	$42.65M	(m)	(m)
2025-09-30	Reported	(m)	-$46.86M	(m)	(m)	(m)	$89.00K*	-$34.78M*	(m)	$37.48M	(m)	(m)
2025-06-30	Reported	(m)	-$42.61M	(m)	(m)	(m)	$50.00K*	-$32.58M*	(m)	$33.56M	(m)	(m)
2025-03-31	Reported	(m)	-$45.96M	(m)	(m)	(m)	$44.00K	-$37.87M	(m)	$36.76M	(m)	(m)
2024-09-30	Reported	(m)	-$40.43M	(m)	(m)	(m)	$520.00K*	-$27.37M*	(m)	$32.22M	(m)	(m)
2024-06-30	Reported	(m)	-$38.11M	(m)	(m)	(m)	$221.00K*	-$26.10M*	(m)	$30.68M	(m)	(m)
2024-03-31	Reported	(m)	-$34.75M	(m)	(m)	(m)	$297.00K	-$28.60M	(m)	$27.69M	(m)	(m)
2023-09-30	Reported	(m)	-$29.45M	(m)	(m)	(m)	$457.00K*	-$22.06M*	(m)	$23.79M	(m)	(m)
2023-06-30	Reported	(m)	-$25.34M	(m)	(m)	(m)	$759.00K*	-$20.23M*	(m)	$19.56M	(m)	(m)
2023-03-31	Reported	(m)	-$25.70M	(m)	(m)	(m)	$4.37M	-$22.83M	(m)	$19.88M	(m)	(m)
2022-09-30	Reported	(m)	-$18.26M	(m)	(m)	(m)	$1.33M*	-$11.96M*	(m)	$13.89M	(m)	(m)
2022-06-30	Reported	(m)	-$16.49M	(m)	(m)	(m)	$554.00K*	-$16.25M*	(m)	$12.40M	(m)	(m)
2022-03-31	Reported	(m)	-$14.83M	(m)	(m)	(m)	$369.00K	-$12.57M	(m)	$11.12M	(m)	(m)
2021-09-30	Reported	(m)	-$13.08M	(m)	(m)	(m)	$451.00K*	-$8.26M*	(m)	$9.88M	(m)	(m)
2021-06-30	Reported	(m)	-$10.46M	(m)	(m)	(m)	$76.00K*	-$9.77M*	(m)	$7.86M	(m)	(m)
2021-03-31	Reported	(m)	-$6.86M	(m)	(m)	(m)	$62.00K	-$6.06M	(m)	$5.36M	(m)	(m)
2020-09-30	Reported	(m)	-$3.64M	(m)	(m)	(m)	$6.00K*	-$3.27M*	(m)	$3.24M	(m)	(m)
2020-06-30	Reported	(m)	-$3.96M	(m)	(m)	(m)	$188.00K*	-$3.98M*	(m)	$3.64M	(m)	(m)
2020-03-31	Reported	(m)	-$3.25M	(m)	(m)	(m)	$9.00K	-$2.74M	(m)	$2.97M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$191.41M	(m)	(m)	(m)	$256.00K	-$143.82M	(m)	$151.39M	(m)	$4.00K
2024-12-31	Reported	(m)	-$158.83M	(m)	(m)	(m)	$1.31M	-$109.03M	(m)	$126.97M	(m)	$3.00K
2023-12-31	Reported	(m)	-$114.36M	(m)	(m)	(m)	$5.75M	-$91.95M	(m)	$90.91M	(m)	$4.00K
2022-12-31	Reported	(m)	-$71.66M	(m)	(m)	(m)	$5.55M	-$52.63M	(m)	$54.03M	(m)	$0.00
2021-12-31	Reported	(m)	-$43.22M	(m)	(m)	(m)	$668.00K	-$33.51M	(m)	$32.19M	(m)	$0.00
2020-12-31	Reported	(m)	-$17.19M	(m)	(m)	(m)	$203.00K	-$14.63M	(m)	$14.98M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Viking Therapeutics, Inc. (VKTX)	United States	$4.287B	-8.51
Indivior Pharmaceuticals, Inc. (INDV)		$4.250B	14.09
Tango Therapeutics, Inc. (TNGX)	United States	$4.154B	-42.53
Veradermics, Inc (MANE)	United States	$4.839B
AbCellera Biologics Inc. (ABCL)		$3.879B	-14.59
Erasca, Inc. (ERAS)	United States	$5.073B	-19.96
Dianthus Therapeutics, Inc. /DE/ (DNTH)	United States	$5.082B	-27.79
ACADIA PHARMACEUTICALS INC (ACAD)	United States	$3.823B	11.45
PTC THERAPEUTICS, INC. (PTCT)	United States	$5.199B	-177.07
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27